ENDRA Q3 net loss $3.4M; cash $8.0M; 95 TAEUS scans YTD, De Novo submission near

ENDRA Life Sciences Inc.

Net loss $3.4 million ($0.05 per share) vs $2.7 million loss ($0.06) in Q3 2021.
Cash and equivalents $8.0 million as of Sept 30, 2022; operating expenses rose to $3.4M from $2.7M.
Nearly doubled TAEUS scans to 95 YTD; collecting final data for FDA De Novo submission for liver device.
Expanded IP portfolio to 56 issued patents; eight new patents added in Q3.
Management reiterates cash sufficient to fund through key milestones including European commercialization and U.S. regulatory submission.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported third quarter of 2022 results: net income $3.4 million, EPS $0.05 per share.

Period: third quarter of 2022
Net income: $3.4 million
EPS: $0.05 per share
Result: reported results

Exact text from the filing

Net loss in the third quarter of 2022 was $3.4 million, or $0.05 per share

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-015284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.